Transforming growth factor beta market was valued at $1,100.4 million in 2025 and is projected to reach $1,618.0 million by 2035, growing at a CAGR of 4% during the forecast period (2026-2035). A large and steadily increasing number of clinical trials globally is strengthening the development landscape for therapies targeting transforming growth factor beta. As research intensifies across oncology, fibrosis, autoimmune disorders, and rare diseases, TGF-? has emerged as a critical biological pathway due to its central role in cell proliferation, immune regulation, and tissue remodeling. The expansion of early- and mid-stage clinical pipelines reflects growing scientific confidence in targeting this pathway. For instance, in November 2025, Society for Immunotherapy of Cancer Annual Meeting, Tiumbio Co., Ltd. presented interim Phase II results for Tosposertib (TU2218) in combination with Keytruda as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company plans to expand global clinical trials and accelerate patient enrollment to support regulatory approval and broader indication development for the novel dual TGF-?/VEGF inhibitor. Pharmaceutical and biotechnology companies are allocating greater resources toward translational research to validate TGF-? as a therapeutic target. This heightened clinical activity is fostering innovation in monoclonal antibodies, small molecule inhibitors, and combination immunotherapies.
Browse the full report description of “Transforming Growth Factor Beta Market Size, Share & Trends Analysis Report by Type (Beta 1, Beta 2, Beta 3 and Beta 4), and by Application (Wound Healing, Angiogenesis, Cancer and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/transforming-growth-factor-beta-market
Simultaneously, the rise in clinical investigations has contributed to increasing grant for antibodies targeting tgfß. Academic institutions, biopharmaceutical firms, and research organizations are prioritizing collaborative programs aimed at advancing targeted biologics. For instance, in July 2024, XOMA Corp. secured US patent US12071475B2 covering novel IgG2 antibodies targeting transforming growth factor beta (TGF?1, TGF?2, and TGF?3) for potential therapeutic use. The patented antibodies are designed with specific amino acid sequences and may be formulated into pharmaceutical compositions to treat cancers, fibrotic disorders, and other TGF?-associated diseases. The development strengthens XOMA’s immunology-focused patent portfolio and supports broader clinical applications aimed at modulating immune responses in oncology and chronic diseases. Antibody therapies are gaining particular attention due to their specificity and potential to modulate complex signaling pathways with improved safety profiles. As more investigational candidates progress through clinical phases, demand for high-quality reagents, biomarker assays, and development platforms continues to expand. This ecosystem of clinical validation and grant for antibodies targeting transforming growth factor beta (tgfß) is strengthening the commercial viability of TGF-?–focused innovations.
Key Players and Recent Developments
The major players present in the global transforming growth factor beta market include AbbVie Inc., Bristol-Myers Squibb Co., Eli Lilly and Company, Pfizer Inc. and Roche Holding AG, among others. These leading companies are actively advancing TGF-?–targeted therapies through robust oncology pipelines, strategic collaborations, and combination immunotherapy approaches to address tumor microenvironment resistance mechanisms.
Market Coverage
Key questions addressed by the report.
Global Transforming Growth Factor Beta Market Report Segment
By Type
By Application
Global Transforming Growth Factor Beta Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/transforming-growth-factor-beta-market